Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Leung

Pediatric Gastroenterology Houston, TX Medical Doctor

NPI 1861699654 CMS profile 416455

6621 Fannin St, Ccc 1010.00, Houston, TX 77030

Open in the dashboard

General payments

$30,551

26 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$338,642 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Daniel Leung of Houston, TX is reported in the CMS Open Payments database as having received $30,551 across 26 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $338,642 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $9,200 1
2023 General $6,285 3
2022 General $4,999 2
2020 General $1,750 1
2019 General $8,317 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Leung
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Daniel Leung were reported at $0. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Daniel Leung Pediatric Gastroenterology median Middle half National median
2019 $8,317 $131 $41–$311 $163
2020 $1,750 $79 $23–$223 $114
2021 $0 $104 $32–$321 $132
2022 $4,999 $125 $37–$331 $149
2023 $6,285 $169 $55–$440 $160
2024 $9,200 $196 $73–$563 $164
2025 $0 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Mallinckrodt Hospital Products Inc. $9,200 1 payment
  2. Gilead Sciences, Inc. $8,652 18 payments
  3. Vertex Pharmaceuticals Incorporated $4,973 1 payment
  4. Merck Sharp & Dohme Corporation $4,125 3 payments
  5. AstraZeneca UK Limited $3,575 2 payments
  6. Albireo Pharma, Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $24,100 8 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,973 1 payment
  3. Travel and Lodging $1,152 7 payments
  4. Food and Beverage $326 10 payments
Products named General payments · program years 2019–2024
  1. TERLIVAZ $9,200 1 payment
  2. MK-5172 $4,125 3 payments
  3. Vemlidy $2,710 1 payment
  4. Bylvay $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

26 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record